Associate Professor Justine Smith, FRANZCO
Uveitis poses a high annual cost to society, primarily because more cases begin during the working years than at any other period in life. Present treatments are crude. We use potentially toxic forms of systemic immunosuppression that fail to target the eye specifically. Even new local therapies act relatively non-specifically. More effective and safer future biologic therapies will target the molecular and cellular mediators of the inflammation. For uveitis to be manifest, the ocular vascular endothe-lium must permit leukocytes or microbes to cross from the circulation into the eye. Movement is controlled by molecules expressed on the endothelium. Our research focuses on identifying these molecular mediators and evaluating their potential as new targets for highly specific therapies of uveitis
GLISTENINGS IN INTRAOCULAR LENSES IN AUSTRALIA AND NEW ZEALAND- A COLLABORATIVE SURGICAL QUALITY AUDIT OVER THE 24 MONTH PERIOD UP TO FEBRUARY 2017. FINDINGS OF THIS AUDIT OF LENSES IMPLANTED BETWEEN 1995 AND 2016, HIGHLIGHT THE ONGOING PRESENCE AND SEVERITY OF VACUOLES EVEN IN THE MOST RECENTLY IMPLANTED LENSES.